As the industry has transitioned much of its R&D expertise into large molecule therapies, an emerging approach could provide a revolutionary treatment tool.
There is plenty of evidence that next-generation sequencing (NGS) for lung cancer can improve patient outcomes and save healthcare systems money, but access across Europe
Just a month after AbbVie and Genmab got FDA approval for Epkinly in one form of non-Hodgkin’s lymphoma, the partners are now preparing to file for a second.
Last year, Nkarta was celebrating data which showed that its natural killer (NK) cell therapy for acute myeloid leukaemia (AML) was showing remarkable efficacy in hard-to-
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
